Letrent, K. J.: search on Z-Library

The world's largest scientific articles store. 70,000,000+ articles for free.

Don't use scam websites

1

PI-13Pharmacokinetics and pharmacodynamics of a HER2 tyrosine kinase inhibitor CP-724714 in patients with advanced malignant HER2 positive solid tumors

GUO, F, LETRENT, S, NOE, D, QIN, A, ROHRBACHER, K, MUNSTER, P, TOLCHER, A, BRITTEN, C, GELMON, K, SHARMA, A

Journal:

Clinical Pharmacology & Therapeutics

Year:

2006

Language:

english

File:

PDF, 48 KB

english, 2006

2

PII-70A population pharmacokinetic analysis of a HER2 tyrosine kinase inhibitor CP-724714 in patients with advanced malignant HER2 positive solid tumors

GUO, F, LETRENT, S, SHARMA, A

Journal:

Clinical Pharmacology & Therapeutics

Year:

2006

Language:

english

File:

PDF, 48 KB

english, 2006

3

Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors

Feng Guo, Stephen P. Letrent, Amarnath Sharma

Journal:

Cancer Chemotherapy and Pharmacology

Year:

2007

Language:

english

File:

PDF, 281 KB

english, 2007

4

Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety

Feng Guo, Stephen P. Letrent, Pamela N. Munster, Carolyn D. Britten, Karen Gelmon, Anthony W. Tolcher, Amarnath Sharma

Journal:

Cancer Chemotherapy and Pharmacology

Year:

2008

Language:

english

File:

PDF, 382 KB

english, 2008

5

A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer

Olivier Rixe, Sandra X. Franco, Denise A. Yardley, Stephen R. Johnston, Miguel Martin, Banu K. Arun, Stephen P. Letrent, Hope S. Rugo

Journal:

Cancer Chemotherapy and Pharmacology

Year:

2009

Language:

english

File:

PDF, 367 KB

english, 2009

6

Effect of GF120918, a Potent P-glycoprotein Inhibitor, on Morphine Pharmacokinetics and Pharmacodynamics in the Rat

Stephen P. Letrent, Gary M. Pollack, Kenneth R. Brouwer, Kim L. R. Brouwer

Journal:

Pharmaceutical Research

Year:

1998

File:

PDF, 582 KB

1998

7

P-glycoprotein-mediated transport of morphine in brain capillary endothelial cells

Stephen P. Letrent, Joseph W. Polli, Joan E. Humphreys, Gary M. Pollack, Kenneth R. Brouwer, Kim L.R. Brouwer

Journal:

Biochemical Pharmacology

Year:

1999

Language:

english

File:

PDF, 318 KB

english, 1999

8

Use of Transdermal Amitriptyline Gel in a Patient with Chronic Pain and Depression

Dr. Mollie A. Scott, Dr. Kristen J. Letrent, Dr. Kellie L. Hager, Dr. Jennifer L. Burch

Journal:

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

Year:

1999

Language:

english

File:

PDF, 28 KB

english, 1999

9

Lack of a Fluoxetine Effect on Prednisolone Disposition and Cortisol Suppression

Stanley W. Carson, Kristen J. Letrent, Michael Kotlyar, George Foose, Manuel E. Tancer

Journal:

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

Year:

2004

Language:

english

File:

PDF, 154 KB

english, 2004

10

Increased brain P-glycoprotein in morphine tolerant rats

Christina L. Aquilante, Stephen P. Letrent, Gary M. Pollack, Kim L.R. Brouwer

Journal:

Year:

1999

Language:

english

File:

PDF, 416 KB

english, 1999

11

334 First-in-human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral cp-724, 714, a selective, small molecule inhibitor of her2 in patients with advanced cancer

P.N. Munster, A.W. Tolcher, C.D. Britten, K. Gelmon, S. Moulder, S. Minton, M. Mita, D. Noe, K.J. Pierce, S.P. Letrent

Journal:

European Journal of Cancer Supplements

Year:

2004

Language:

english

File:

PDF, 149 KB

english, 2004

12

Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors

Rini, B. I., Schiller, J. H., Fruehauf, J. P., Cohen, E. E. W., Tarazi, J. C., Rosbrook, B., Bair, A. H., Ricart, A. D., Olszanski, A. J., Letrent, K. J., Kim, S., Rixe, O.

Journal:

Clinical Cancer Research

Year:

2011

Language:

english

File:

PDF, 244 KB

english, 2011

13

Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer

Ramalingam, S. S., Blackhall, F., Krzakowski, M., Barrios, C. H., Park, K., Bover, I., Seog Heo, D., Rosell, R., Talbot, D. C., Frank, R., Letrent, S. P., Ruiz-Garcia, A., Taylor, I., Liang, J. Q., Ca

Journal:

Journal of Clinical Oncology

Year:

2012

Language:

english

File:

PDF, 194 KB

english, 2012

14

Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non–Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib

Park, Keunchil, Cho, Byoung C., Kim, Dong-Wan, Ahn, Myung-Ju, Lee, Sang-Yoon, Gernhardt, Diana, Taylor, Ian, Campbell, Alicyn K., Zhang, Hui, Giri, Nagdeep, Letrent, Stephen P., O’Connell, Joseph, Heo

Journal:

Journal of Thoracic Oncology

Year:

2014

Language:

english

File:

PDF, 669 KB

english, 2014

15

Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer

Boyer, Michael, Jänne, Pasi Antero, Mok, Tony, O’Byrne, Kenneth, Paz-Ares, Luis, Ramalingam, Suresh S, Liang, Jane, Taylor, Ian, Campbell, Alicyn, O’Connell, Joseph, Letrent, Stephen, Antic, Vladan

Journal:

Clinical Investigation

Year:

2013

Language:

english

File:

PDF, 3.39 MB

english, 2013

16

First Study of the Safety, Tolerability, and Pharmacokinetics of CP-724,714 in Patients with Advanced Malignant Solid HER2-Expressing Tumors

Munster, P. N., Britten, C. D., Mita, M., Gelmon, K., Minton, S. E., Moulder, S., Slamon, D. J., Guo, F., Letrent, S. P., Denis, L., Tolcher, A. W.

Journal:

Clinical Cancer Research

Year:

2007

Language:

english

File:

PDF, 279 KB

english, 2007

17

Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors

Janne, P. A., Boss, D. S., Camidge, D. R., Britten, C. D., Engelman, J. A., Garon, E. B., Guo, F., Wong, S., Liang, J., Letrent, S., Millham, R., Taylor, I., Eckhardt, S. G., Schellens, J. H. M.

Journal:

Clinical Cancer Research

Year:

2011

Language:

english

File:

PDF, 385 KB

english, 2011

18

Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients

Socinski, Mark A, Mudd, Paul N, Radomski, Kristine M, Steagall, Ann, Lawrence, Pam, Bernard, Stephen, Letrent, Stephen P, Gonzalez, Pablo, Brouwer, Kim LR

Journal:

Anti-Cancer Drugs

Year:

1998

File:

PDF, 682 KB

1998

19

Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab

Ather, Ferdows, Hamidi, Habib, Fejzo, Marlena S., Letrent, Stephen, Finn, Richard S., Kabbinavar, Fairooz, Head, Christian, Wong, Steven G., Cordes, Nils

Journal:

Year:

2013

Language:

english

File:

PDF, 2.73 MB

english, 2013

20

Negative outcomes from drug interactions involving cimetidine in older ambulatory care patients

Scott, Mollie A., Letrent, Kristen J., Martz, Michael D.

Journal:

American Journal of Health-System Pharmacy

Year:

1999

Language:

english

File:

PDF, 48 KB

english, 1999

21

Negative outcomes from drug interactions involving cimetidine in older ambulatory care patients

Scott, Mollie A., Letrent, Kristen J., Martz, Michael D.

Journal:

American Journal of Health-System Pharmacy

Year:

1999

File:

PDF, 48 KB

1999

22

Consider potential for drug interactions during formulary review

Scott, Mollie Ashe, Letrent, Kristen J., Martz, Michael D.

Journal:

American Journal of Health-System Pharmacy

Year:

2000

File:

PDF, 59 KB

2000

23

134TiP A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2â primary breast cancer: CheckMate 7FL

Curigliano, G., McArthur, H., Harbeck, N., Pusztai, L., Delaloge, S., Letrent, K., Chen, T., Li, B., Tatsuoka, K., Zardavas, D., Loi, S.

Journal:

Annals of Oncology

Year:

2020

File:

PDF, 94 KB

2020

24

First-Line Dacomitinib (PF-00299804), an Irreversible Pan-Her Tyrosine Kinase Inhibitor, for Patients with EGFR-Mutant Lung Cancers

Kris, M.G., Mok, T., Ou, S.-H.I., Martins, R.G., Kim, D.-W., Goldberg, Z., Zhang, H., Taylor, I., Letrent, S.P., JÃ¤nne, P.A.

Journal:

Annals of Oncology

Year:

2012

File:

PDF, 56 KB

2012

25

Critical Management Studies at Work || Introduction: Intersections of Critical Management Research and Practice: A Multi-Domain Perspective

Wolfram Cox, Julie, LeTrent-Jones, Tony, Voronov, Maxim, Weir, David

Year:

2009

File:

PDF, 90 KB

2009